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Abstract
Background: An imbalance between overwhelming inflammation and lymphocyte apoptosis is the main cause of high
mortality in patients with sepsis. Baicalin, the main active ingredient of the Scutellaria root, exerts anti-inflammatory, anti-
apoptotic, and even antibacterial properties in inflammatory and infectious diseases. However, the therapeutic effect of
baicalin on polymicrobial sepsis remains unknown.
Methodology/Principal Findings: Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) in C57BL/6 mice.
Mice were infused with baicalin intraperitoneally at 1 h, 6 h and 12 h after CLP. Survival rates were assessed over the
subsequent 8 days. Bacterial burdens in blood and peritoneal cavity were calculated to assess the bacterial clearance.
Neutrophil count in peritoneal lavage fluid was also calculated. Injuries to the lung and liver were detected by hematoxylin
and eosin staining. Levels of cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-10 and IL-17, in
blood and peritoneum were measured by enzyme-linked immunosorbent assay. Adaptive immune function was assessed
by apoptosis of lymphocytes in the thymus and counts of different cell types in the spleen. Baicalin significantly enhanced
bacterial clearance and improved survival of septic mice. The number of neutrophils in peritoneal lavage fluid was reduced
by baicalin. Less neutrophil infiltration of the lung and liver in baicalin-treated mice was associated with attenuated injuries
to these organs. Baicalin significantly reduced the levels of proinflammatory cytokines but increased the level of anti-
inflammatory cytokine in blood and peritoneum. Apoptosis of CD3
+ T cell was inhibited in the thymus. The numbers of
CD4
+, CD8
+ T lymphocytes and dendritic cells (DCs) were higher, while the number of CD4
+CD25
+ regulatory T cells was
lower in the baicalin group compared with the CLP group.
Conclusions/Significance: Baicalin improves survival of mice with polymicrobial sepsis, and this may be attributed to its
antibacterial property as well as its anti-inflammatory and anti-apoptotic effects.
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Introduction
Sepsis and sequential multiple organ failure/dysfunction
syndrome (MOF/MODS) remain to be the leading cause of
death in intensive care units, despite the progression of medical
care [1,2]. The sepsis response may begin with an infectious
nidus. In the early phase of sepsis, overwhelming inflammatory
response is initiated after microbial infection [3]. During this
stage, cytokine storm is triggered, as well as excessive
neutrophils recruitment in multiple organs, complement system
activation and coagulation dysfunction. This proinflammatory
state has been defined as being a systemic inflammatory
response syndrome (SIRS) [4]. The late hypodynamic phase is
characterized by T cell hyporesponsiveness, defective antigen
presentation and loss of delayed-type hepersensitivity response,
which has been recently termed a compensatory anti-inflam-
matory response syndrome (CARS) [4,5].
Neutrophil activation during the early phase of sepsis induces
organ damage by directly adhering to endothelium which
produces microvascular occlusions or releasing proteolytic en-
zymes and oxygen radicals [6], thus it is reasonable that resolution
of inflammation may improve survival of sepsis. However, clinical
trials show that a single anti-inflammatory treatment such as
neutralization of endotoxin, tumor necrosis factor (TNF) or
interleukin (IL)-1, is inefficient or even detrimental to the host,
as endogenous cytokines are crucial for bacterial clearance and
neutralisation of them may induce immunoparalysis [7–9]. Sepsis
itself may induce immunosuppression in absence of any anti-
inflammatory treatment, as characterized by loss of delayed
hypersensitivity, inability to clear the infection and predisposition
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inflammation and apoptosis are simultaneously activated during
sepsis, as phosphorylation of some kinases, such as extracellular
regulated protein kinases 1 and p38 mitogen-activated protein
kinase 1 (MAPK1), may enhance both proliferation and apoptosis.
Therefore, immunomodulation, which reduces inflammatory load
while preserving immune function, becomes a promising thera-
peutic approach for sepsis.
Baicalin (5,6,7-Trihydroxyflavone) is a main active ingredient
derived from the dried root of Scutellaria, a popular herb in
traditional Chinese medicine used to treat fever [12–13].
Baicalin, a small-molecule monomer, exhibits anti-inflammatory,
anti-oxidant, anti-apoptotic, and antibacterial properties. Studies
in rats with severe acute pancreatitis showed that baicalin
inhibited inflammation and protected multiple organs function
in [14–15]. Baicalin was also reported to inhibit lipopolysac-
charide (LPS)-induced inflammation both in vitro and in vivo. In
vitro, baicalin reduced LPS-stimulated macrophage activation
[16], while in vivo, it inhibited pro-inflammatory cytokines and
nitric oxide (NO) production, nuclear factor-kB (NF-kB)
activation, caspase-3 activity, as well as reversed organ injury
caused by endotoxic shock [16–17]. Moreover, baicalin can
even be used as an adjunctive therapy against methicillin-
resistant Staphylococcus aureus (MRSA) ex vivo and Escherichia
coli (E. coli) meningitis in animals [18–19]. The aglycone
derivative of baicalin, baicalein, is thought to interfere with the
cell wall integrity of bacteria by binding to peptidoglycan.
Interestingly, these special pharmacological actions of baicalin
are all that are required in treatment of polymicrobial sepsis.
Therefore, this study is performed to determine whether baicalin
is effective in improving survival of mice with polymicrobial
sepsis induced by cecal ligation and puncture (CLP). The
potential protective mechanism of baicalin appeares to be
associated with its effects on inflammation, apoptosis and
microbial clearance.
Methods
CLP Model of Sepsis
All experiments were approved by the Animal Care and Use
Committee of Changhai hospital (permission number:CH
20101215-04).Healthy8–10-week-oldC57BL/6malemice,weigh-
ing 22–30 g, were purchased from the Animals Experimentation
Center of Second Military Medical University. All animals were
acclimatized under controlled temperature (2062uC), humidity
(6065%) and 12 h light/12 h dark cycle for 1 week before the
experiment.
The CLP procedure was performed according to the
guidelines of Wichterman et al. [20] Briefly, mice were
completely anesthetized with isofluorane and a midline abdom-
inal incision was made after the abdomen was disinfected. The
cecum was exposed and ligated below the ileocecal valve with a
1–0 Prolene thread. The ligated cecum was then punctured
twice with a 22-gauge needle to induce polymicrobial perito-
nitis. The cecum was slightly compressed until a small drop of
stool appeared. The abdominal wall was closed in 2 layers. For
control purposes, sham-operated mice underwent the same
procedure, including peritoneum opening and bowel exposing,
but without ligation and needle perforation of the cecum. After
surgery, the mice were resuscitated by subcutaneous injection of
1 ml sterile physiologic saline solution. All mice were given free
access to food and water after recovery from anesthesia.
Drug Administration
Baicalin (Sigma-Aldrich; CAS Number: 21967-41-9; purity,
98%; molecular formula, C21H18O11; molecular weight,
446.36), was dissolved in normal saline and the pH of the solution
was adjusted to 7.4 with NaOH. Mice were randomly divided into
three groups: (1) sham group: mice underwent the sham operation
and received normal saline; (2) CLP group: mice were subjected to
CLP and received normal saline; (3) baicalin group: mice were
subjected to CLP and treated with baicalin. Baicalin (100 mg/kg,
200 ml)wasinjectedintraperitoneallyat1 h,6 h,and12 hfollowing
CLP.
Figure 1. Survival rate of septic mice after injection with baicalin. Baicalin improves survival of polymicrobial sepsis in CLP mice. In the bai
group, mice were treated with intra-peritoneal baicalin (100 mg/kg) at 1 h, 6 h and 12 h after CLP. Normal saline of equal volume was administered
in sham and CLP groups. Bai, baicalin group; CLP, CLP group. Survival analyses with log-rank test. ** P,0.01.
doi:10.1371/journal.pone.0035523.g001
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In order to compare the effect of baicalin administration at
different time points after CLP on survival, mice that had
undergone CLP were randomized to receive intraperitoneal
baicalin or saline after CLP (n=16 for each group). Survival
rates were assessed over the subsequent 8 days.
Bacterial Clearance
Blood and peritoneal lavage fluid samples were collected 24 h
after surgery. Blood was collected by heart puncture after
isoflurane anesthesia (n=6 for each group). For peritoneal lavage,
the skin of the abdomen was cut open in the midline after it was
thoroughly disinfected. A total of 2 ml sterile phosphate-buffered
saline (PBS) was injected into and aspirated out of the peritoneal
cavity several times. Samples of peritoneal lavage fliud were
serially diluted to 10, 100, or 1000-fold in 900 ml PBS. Then
100 ml aliquot of each dilution was spread on a tryptic soy agar
blood agar plate. All plates were incubated at 37uC for 24 h.
Colonies were counted and expressed as colony forming units
(CFUs)/ml for all the samples.
Determination of Neutrophil Count in Peritoneal Lavage
Fluid
The peritoneal lavage fluid of the septic and sham-operated
mice was harvested 24 h after CLP (n=6 for each group). After
erythrocytes were lysed, cells were stained with fluorochrome-
conjugated antibody to cell subset-specific surface marker Gr-1 for
neutrophils (Figure S1). Cells were subjected to fluorescence-
activated cell sorting (FACS) and cell numbers were calculated by
flow cytometry (FCM).
Histopathological Studies
The lungs and livers of the septic and sham-operated mice were
harvested 24 h after surgery for histopathological staining, as
previously described. These organ tissues were fixed in buffered
formaldehyde (10% in PBS) for more than 8 h, dehydrated in
graded ethanol, and embedded in paraffin. Four-micrometer
sections were cut and paraffin was removed by xylene. The tissue
sections were then stained with the hematoxylin and eosin reagent
and observed under light microscopy. The total surface of the
slides was scored by two blinded pathologists with expertise in
assessing lung and liver tissues. Briey, the criteria for scoring lung
inammation were as follows [21]: 0,normal tissue; 1, minimal
inammatory change; 2, no obvious damage to the lung architec-
ture; 3, thickening of the alveolar septae; 4, formation of nodules
or areas of pneumonitis that distorted the normal architecture; and
5, total obliteration of the field. A semiquantitative method was
used to evaluate the degree of liver necrosis: 0, none; 1, individual-
cell necrosis; 2, up to 30% lobular necrosis; 3, up to 60% lobular
necrosis; 4, more than 60% lobular necrosis. The slides were
examined by two pathologists who were unaware of the groups.
Measurement of Cytokines
Blood and peritoneal lavage fluid samples from the septic or
sham-operated mice were collected 24 h after surgery (n=6 for
each group). Plasma and supernatant of peritoneal lavage fluid
were collected after centrifugation of the samples (300 g for
Figure 2. Bacterial clearance in blood (A) and peritoneum (B) in septic mice after baicalin treatment. Baicalin enhanced bacterial
clearance in blood (A) and peritoneum (B). Blood and peritoneal lavage fluid were harvested 24 h after CLP. Bai, baicalin group; CLP, CLP group. Data
analyses with one-way ANOVA and Newman-Keuls. ** P,0.01.
doi:10.1371/journal.pone.0035523.g002
Figure 3. The number of neutrophils in peritoneum in septic
mice after administration of baicalin. Baicalin reduced the number
of neutrophils in peritoneum. Peritoneal lavage fluid were harvested
24 h after CLP. Bai, baicalin group; CLP, CLP group. Data analyses with
one-way ANOVA and Newman-Keuls. * P,0.05.
doi:10.1371/journal.pone.0035523.g003
Baicalin Improves Survival of Septic Mice
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e355235 min). Levels of TNF-alpha, IL-6, IL-10, and IL-17 were
measured using the murine enzyme-linked immunosorbent assay
(ELISA) kit (Bender Systems, USA) according to manufacturer’s
instructions.
Quantification of Apoptosis in the Thymus
Thymus tissues were harvested from the septic and sham-
operated mice 24 h after surgery (n=6 for each group), and
single-cell suspensions were prepared. The annexin V-FITC
binding and propidium iodide (PI) staining assay were used to
assess apoptosis of CD3
+ T cells. Stained cells were analyzed via
a FACSCalibur and the CellQuest software (Becton Dickinson,
USA). T Cells positive for CD3 were first analyzed (Figure S4)
and Cells positive for annexin V in CD3
+ T cells were
determined to be apoptotic cells.
Determination of Cell Counts in the Spleen
The spleens of the septic and sham-operated mice were
harvested 24 h after surgery (n=6 for each group) and single-
cell suspensions were prepared. Cells were stained with
fluorochrome-conjugated antibodies to cell subset-specific surface
markers (CD4, CD8 for T cells, CD4CD25 for Tregs, CD19
for B cells and CD11c for DCs) (Figure S3, Figure S2). The
percentage of cells in each group was analyzed by FACS.
Statistical Analysis
Data are reported as the mean 6 SEM. All statistics analyses
were performed using Prism 4.0 (GraphPad Software, USA).
Survival of the 2 subgroups was estimated by Kaplan-Meier
survival curves; comparisons were performed by the log-rank
test. All comparisons among groups were performed by Mann-
Whitney analysis of variance. For multigroup analysis, inter-
Figure 4. Histopathological changs of septic mice after baicalin treatment. The tissues were harvested 24 h after CLP for histopathologic
examination using hematoxylin and eosin staining. Representative images from six animals per group were shown. Histopathological tests showed
milder impairment in lung and liver after baicalin administration. A, After baicalin treatment, lung showed less neutrophil accumulation and alveolar
destruction. B, Hepatocytes were protected and hepatic sinusoid was also preserved in baicalin treated mice. C, the severity of lung injury was scored
as described in Materials and methods. D, the severity of liver injury was scored as above. ** P,0.01 vs. sham. ## P,0.01 vs. CLP. Bai, baicalin group;
CLP, CLP group.
doi:10.1371/journal.pone.0035523.g004
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cance level of 0.05 was considered to be significant for all
calculations.
Results
Baicalin Improves Survival in Mice with Polymicrobial
Sepsis
In order to investigate whether baicalin was benefit to CLP
mice, survival was first assessed at day 8 after CLP. As a result, the
survival rate in the CLP group (25%) was lower than that in the
sham group (100%; P,0.05). Then after baicalin solution
Figure 5. Cytokines expression of septic mice after baicalin injection. Baicalin reduced excretion of proinflammatory cytokines while
increased anti-inflammatory cytokine. Samples were collected 24 h after CLP. Proinflammatory cytokines included TNF-alpha, IL-6 and IL-17 (A, B, D in
blood and E, F, H in peritoneum). IL-10 represented the anti-inflammatory cytokine (C in blood and G in peritoneum). PLF, peritoneal lavage fluid; Bai,
baicalin group; CLP, CLP group. Data analyses with one-way ANOVA and Newman-Keuls. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0035523.g005
Figure 6. Cell counts in the spleen and apoptosis in the thymus in septic mice after baicalin administration. (A) Baicalin increased the
numbers of CD4
+ and CD8
+ T lymphocytes, as well as CD11c
+ dendritic cells, but not CD19
+ B lymphocytes in spleen. (B) Baicalin reduced the number
of regulative T cells in spleen. (C, D) Baicalin inhibited lymphocyte apoptosis in thymus. Bai, baicalin group; CLP, CLP group. Data analyses with one-
way ANOVA and Newman-Keuls. *P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0035523.g006
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survival (81.25%) compared with the CLP group (25%; P,0.05).
(Figure 1).
Baicalin Enhances Bacterial Clearance in Blood and
Peritoneum
Blood and peritoneal lavage fluid samples were collected 24 h
after CLP. Increased bacterial burden was found in the blood and
peritoneal lavage fluid samples in the CLP mice compared with
the sham mice. These data demonstrated that mice treated with
baicalin after CLP showed a significantly reduced bacterial burden
in both blood and peritoneal lavage fluid compared with the CLP
mice (P,0.05) (Figure 2).
Baicalin Reduces the Number of Neutrophils in
Peritoneum
As neutrophils act as the first line of defense against microbial
invasion and the counts of neutrophils migrated to abdominal
reflected their migration ability, we assessed the number of
neutrophils in the abdominal area. Compared with the CLP
group, baicalin significantly decreased the number of neutrophils
in peritoneal cavity (P,0.05) (Figure 3).
Histopathological Tests Show Milder Impairment in the
Lung and Liver after Baicalin Administration
Lung and liver injury was demonstrated by H&E staining. In
CLP mice, lungs were characterized by a large accumulation of
neutrophils, with lots of exudates of red blood cells as well as
impaired alveoli. The livers of CLP mice were characterized by
swollen hepatocytes and no hepatic sinusoids. Administration of
baicalin resulted in significant attenuation of these findings, with
characteristics similar to those of sham-operated mice, and also
reduced the lung and liver injury scores (Figure 4).
Baicalin Reduces Release of Proinflammatory Cytokines
While Increasing Release of Anti-Inflammatory Cytokine
Plasma and peritoneal cytokines levels were assessed to
determine the inflammation status of the mice. In CLP mice,
levels of pro-inflammatory factors IL-6 and TNF-alpha were
significantly increased, while the anti-inflammatory factor IL-10
was decreased in sepsis in both the plasma and peritoneal cavity
24 h after surgery. After baicalin was treated, levels of IL-6 and
TNF-alpha were markedly reduced while the level of IL-10 was
elevated. IL-17A is an important chemotactic cytokine for
neutrophils and plays a detrimental role in sepsis. As expected,
baicalin treatment reduced the level of IL-17A in plasma and
peritoneal lavage fluid compared with the CLP group (P,0.05)
(Figure 5).
Cell Counts in the Spleen and Apoptosis in the Thymus
CLP-induced immunosuppression is characterized by increased
apoptosis and hence reduced lymphocyte counts. Baicalin
significantly increased the counts of CD4
+ T lymphocytes, CD8
+
T lymphocytes and DC cells in the spleen compared with the CLP
group (P,0.05), with no remarked difference in B cells (CD19
+)
counts between the 2 groups (P.0.05). Treg (CD4
+CD25
+) counts
were lower in the baicalin group compared with the CLP group
(P,0.05) (Figure 6). In the thymus, mice treated with baicalin had
a significant reduction in the number of apoptotic CD3
+ T
lymphocytes compared with the CLP group (P,0.05) (Figure 6).
Discussion
This study for the first time examined the effects of baicalin on
polymicrobial sepsis induced by CLP. Baicalin administration had
been suggested to protect lung and liver, enhance bacterial
clearance, and improve survival in sepsis in our study. It was
interesting to notice that the therapeutic effect of baicalin in sepsis
seemed to be associated with several different aspects of sepsis,
including attenuated excessive inflammatory response, preserved
adaptive immune reaction and enhanced bacterial clearance.
According to our present study, baicalin inhibited neutrophil
mobilization and promoted a shift from pro-inflammatory to anti-
inflammatory response. On the other hand, apoptosis of T cells in
thymus was markedly inhibited following baicalin treatment. In
line with these findings, baicalin enhanced the numbers of splenic
T cells and DC cells and inhibited the production of Tregs
(CD4
+CD25
+ T cell).
It is generally accepted that uncontrolled inflammation is the
main factor contributing to organ dysfunction and death during
sepsis [6,22]. After entry into the host, the pathogens is recognized
by pathogen recognition receptors (PRRs, which are receptors
recognizing pathogen- or danger-associated molecular patterns,
such as Toll-like receptors), leading to activation of intracellular
signaling, such as NF-kB, and further amplifying the inflammatory
responses [23]. Neutrophils, abnormally activated by the over-
whelming cytokine production, release proteolytic enzymes and
reactive oxygen species (ROS), which finally lead to multiple organ
dysfunction [6]. Circulating pro-inflammatory mediators are
always greatly upregulated in septic patients and some of them
are considered to be diagnostic and prognostic biomarkers, such as
C-reactive protein (CRP), IL-6 and IL-8 [24–25]. Studies on
genetic polymorphism also showed higher severity and mortality in
septic patients that harbor a genotype expressing higher levels of
TNF-alpha, interferon-gamma, IL-1, and IL-6 [26–27]. Here we
demonstrated that baicalin, as an anti-inflammatory agent,
reduced neutrophil migration as well as circulating and peritoneal
pro-inflammatory factors. For example, we noted that baicalin
reduced the level of IL-17A in blood and peritoneum. IL-17A is a
proflammatory cytokine and is a mediator of neutrophil stimula-
tion and mobilization by T lymphocytes in sepsis [28]. Yang Ji et
al. reported that baicalin suppressed RORct-mediated IL-17
expression in established TH.17 cells [29], which is consistent with
our study. Baicalin also greatly improved organ integrity. Zhang et
al. reported similar results in a rat model of severe acute
pancreatitis [15]. They found that after treating rats with baicalin,
levels of IL-1b, thromboxane B2, and phospholipase A2 in blood
were significantly reduced, and inflammation of pancreas was
greatly attenuated. Thus, baicalin can protect organ function
against overwhelming inflammatory response during sepsis.
Althought anti-inflammatory treatment of sepsis is associated
with increased risk of inability to eliminate the offending bacteria,
we found that baicalin treatment enhanced bacterial clearance.
We found a smaller number of peritoneal neutrophils in baicalin-
treated mice, and although this result might reflect a compromised
innate immune function, it was recently identified that neutrophils
were dispensable for defense against bacterial infection [30]. That
study showed that fewer neutrophils migration was compensated
by macrophages or adaptive immune responses. Enhanced
adaptive immune function might be a critical factor contributing
to the therapeutic effect of baicalin against sepsis, as demonstrated
by an increased number of T lymphocytes as well as reduced
lymphocyte apoptosis and Treg levels in the spleen. Massive
apoptosis of lymphocytes is one of the main characters of patients
with severe sepsis and renders the patients susceptible to secondary
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a promising treatment for sepsis [31] and multiple studies have
demonstrated that anti-apoptotic agents improved survival in
septic mice [32–35]. Therefore, inhibition of lymphocyte apoptosis
by baicalin is crucial for its therapeutic effect despite of the
attenuated inflammatory responses.
However, the mechanism underlying the anti-apoptotic effect of
baicalin remains unclear. Compromised inflammatory response
might be one of the causes. At a very early stage of sepsis, although
baicalin blocked initiation of inflammatory responses, neutrophil-
or macrophage-derived cytokines, such as TNF-alpha, ROS, and
NO, might trigger apoptosis [36]. Moreover, baicalin was shown
to be capable of prevent apoptosis in LPS-induced cardiomyocyte
apoptosis and ischemia-induced neuron apoptosis by inhibiting
caspase-3 activity [17]. Baicalin might inhibit lymphocyte apop-
tosis by attenuating uncontrolled inflammatory responses or
directly blocking caspase-3.
It is reported that polymicrobial sepsis increases the number of
splenic CD4
+CD25
+ Tregs after CLP [37]. Tregs suppress effector
cells activity, weakening the body’s immune founction during
sepsis. However, baicalin exhibits an important protective effect in
sepsis induced by CLP. Baicalin treatment weakens the negative
regulatory role of Tregs by reducing the number of Tregs or
another mechanism altogether. Specific pathways will be further
explored in future.
It was amazing that baicalin acted as a synergistic agent with
antibiotics against bacteria in several studies in vitro, including
vancomycin-resistant Enterococcus and MRSA [18,38]. Baicalin might
bind to peptidoglycan on the surface of bacteria and interfere with
the integrity of cell wall, much like a cell wall-active antibiotic.
Another study also demonstrated that when baicalin was given as
an adjunctive therapy to ampicillin, it defended the host against E.
coli-induced meningitis in vivo [19]. According to the present study,
baicalin itself might have an anti-bacterial activity in the treatment
of sepsis.
The major limitation of this study is that we have not
progressively explored the specific mechanism underlying the
anti-inflammatory and anti-apoptotic effects of baicalin. Since
there is hardly any efficient treatment against sepsis up to now,
baicalin may be a promising agent in the treatment of this
potentially fatal condition. Further studies should aim to uncover
the mechanism underlying the anti-inflammatory and anti-
apoptotic effects of baicalin, as well as to examine the efficacy of
baicalin in patients in the clinical setting.
In conclusion, based on the results of this study, baicalin seems
to be effective in treating sepsis in mice. Baicalin improves survival
of mice with polymicrobial sepsis, which may be attributed to its
antibacterial property as well as its anti-inflammatory and anti-
apoptotic effects.
Supporting Information
Figure S1 Gating on Gr-1
+ neutrophils in peritoneum.
Compared with the CLP group, the number of Gr-1
+ neutrophils
in mice treated with baicalin was decreased.
(TIF)
Figure S2 Gating on CD11c
+ DCs and CD19
+ B cells in
the spleen. Baicalin increased the numbers of CD 11c
+ dendritic
cells, but not CD19
+ B lymphocytes in the spleen.
(TIF)
Figure S3 Gating on CD4
+ T, CD8
+ T and CD4
+CD25
+ T
Cells (Tregs) in the spleen. Baicalin increased the numbers of
CD4
+ and CD8
+ T lymphocytes, but reduced the number of
regulative T cells in the spleen.
(TIF)
Figure S4 Gating on CD3
+ T cells in the thymus.
Apoptosis of CD3
+ T cells in the thymus was inhibited after
treatment with baicalin.
(TIF)
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